/

2126.HK

JW THERAP-BClosed

2.69−0.17 −6.12%HKD

HKSE · as of Oct 14, 04:08 ET · 15m delay

Open

2.86

Prev close

2.86

Day range

2.692.86

52-week range

1.404.18

Volume

1.38M0.96×

Mkt cap

1.12B

P/E ttm

—

Fwd P/E

-3.07

EPS ttm

-0.9200

Div yield

0.00%

Earnings

—

From 52w high

−35.77%

Price Chart

Yahoo Finance · delayed

2126.HKOct 14, 2026O 2.86H 2.86L 2.68C 2.68−0.17 (−6.12%)Vol 1.38M

SMA 502.24
SMA 2002.16

1Y change −32.37% since Oct 13, 2025 close529 bars loadedTimes in Asia/Hong_KongDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

2126.HK JW THERAP-B · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −8.52%
1 month: +35.61%
3 months: +47.53%
6 months: +13.29%
Year to date: +6.55%
1 year: −29.90%

Valuation & ownership

Market cap: 1.12B
Enterprise value: 1.02B
P/E (ttm): —
Forward P/E: -3.07
PEG ratio: —
Price / book: 2.05
Price / sales (ttm): 3.88
EV / EBITDA: -6.31
EPS (ttm): -0.9200
EPS (forward): -0.8744
Beta (5y monthly): 1.79
Dividend yield: 0.00%
Payout ratio: —
Shares outstanding: 416.73M
Float: 320.54M
Short % of float: —
Short ratio (days): —
Held by insiders: 23.84%
Held by institutions: 0.25%
Avg volume (3m): 1.43M
50-day average: 2.22
200-day average: 2.15
52-week change: −29.90%
S&P 500 52-week: +17.00%

Technicals (daily)

RSI (14): 54.3
vs 50-day SMA: +19.99%
vs 200-day SMA: +24.24%
50 / 200-day trend: ▲ 50 above 200
MACD vs signal: ▼ below
ATR (14) % of price: 7.99%
Realised vol (20d, ann.): 98.2%
From 52-week high: −35.77%
From 52-week low: +91.79%

ANR

Analyst Consensus

No analyst coverage for this instrument.

Financial Snapshot

Full statements →trailing twelve months

Revenue (ttm): 288.66M
Revenue growth (yoy): +4.70%
Earnings growth (yoy): —
Gross margin: 57.39%
Operating margin: -83.48%
Profit margin: -117.25%

DES

About JW THERAP-B

Yahoo Finance profile

JW (Cayman) Therapeutics Co. Ltd, a clinical stage cell therapy company, engages in the research and development, manufacture, and marketing of cellular immunotherapy products in the People's Republic of China. The company offers cell-based immunotherapies, including CAR-T treatment, a treatment method that uses human immune cells to fight cancer. It offers Carteyva, JWCAR201, and JWCAR239 for the treatment of hematological malignancies, advanced relmacabtagene autoleucel injection (relma-cel) as a potential treatment for systemic lupus erythematosus (SLE), and progressed development of products for the treatment of solid tumors, as well as systemic lupus erythematosus (SLE), a chronic autoimmune disease. The company's products pipeline includes JWCAR129, a chimeric antigen receptor (CAR) construct therapy for use in the treatment of multiple myeloma; and JWCAR201, a dual targeting autologous CAR T-cell therapy for use in the treatment of B-cell malignancies and autoimmune diseases. It is also developing JWATM204 and JWATM214 for treating hepatocellular carcinoma (HCC); JWATM203 for the treatment of hepatoblastoma (HB) and hepatocellular carcinoma (HCC) in pediatric patients; JWATM213 for treating HCC; JWTCR001 for the treatment of various solid tumors; and JWCAR031 for the treatment of small cell lung cancer. In addition, the company engages in drug research and development; medical research and experimental development; import and export handling; and clinical trial and CRO, as well as investment holding activities. JW (Cayman) Therapeutics Co. Ltd was founded in 2016 and is headquartered in Shanghai, China.

Sector: Healthcare
Industry: Biotechnology
Employees: 303
Headquarters: Shanghai, China
Website: jwtherapeutics.com
Officers

SEAS

Seasonality · 2126.HK

2020–2026 · monthly returns

Strongest month Nov +15.86%Weakest month Mar −16.75%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	-4.0	-9.1	-12.7	21.4	-15.0	-19.2	0.6	28.6	36.5	-5.0			+6.5%
2025	8.6	38.1	-12.0	-9.5	30.1	43.7	81.5	-9.1	-7.2	-20.5	-10.3	-19.2	+96.9%
2024	-25.7	28.0	-14.9	-2.2	30.2	-15.9	-9.7	-24.3	38.1	-25.9	-5.1	-1.5	−43.4%
2023	21.8	-16.2	-17.8	-9.6	-13.0	-10.5	9.7	-19.9	-8.4	2.9	54.0	-31.1	−48.0%
2022	-33.0	10.2	-18.0	-10.2	2.5	8.4	-17.8	-8.0	-48.5	-11.4	52.5	1.9	−67.5%
2021	41.4	5.1	-21.1	5.5	-10.6	-14.3	-18.0	-19.3	-9.6	-4.0	-11.7	6.0	−49.0%
2020												6.7	+6.7%

INSD

Insider Activity · 2126.HK

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

0 shares

Sells, 6 months

— shares

Net shares

Net change in insider shares

—

Date	Insider	Transaction	Shares	Value
Jul 21, 2026	Tian (Feng)Chief Executive Officer	Acquisition at price 0.22 per share.	44K	$9.68K
Jul 16, 2026	Tian (Feng)Chief Executive Officer	Acquisition at price 0.22 per share.	25K	$5.43K
Jul 15, 2026	Tian (Feng)Chief Executive Officer	Acquisition at price 0.24 per share.	37.5K	$8.91K
Jul 9, 2026	Tian (Feng)Chief Executive Officer	Acquisition at price 0.23 per share.	44K	$10.10K
Jul 6, 2025	Li (Yiping James)Director (Non-Executive)	—	1.21M	—

2126.HK

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

2126.HK

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

Financial Snapshot

About JW THERAP-B

Seasonality · 2126.HK

Insider Activity · 2126.HK

Congress Trades · 2126.HK

Investors Holding 2126.HK

Investors Holding 2126.HK

Congress Trades · 2126.HK

Insider Activity · 2126.HK

Seasonality · 2126.HK

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

Financial Snapshot

About JW THERAP-B

Earnings & Dividends

News